Nyxoah SA (NYXH) Form 424B5 — Jun 8, 2026
Nyxoah SA (NYXH) is offering 55.2 million ordinary shares at $1.72 per share, raising approximately $88.5 million in net proceeds to fund US commercialization of its FDA-approved Genio sleep apnea device and extend its cash runway into late 2026. The offering represents significant dilution, increasing the share count by roughly 26% and resulting in an immediate dilution of $0.98 per share for new investors, as the offering price exceeds the company's negative net tangible book value of $(0.36) per share.
Key figures
- Total Debt
- 61727000
- Net Proceeds
- 88500000
- Cash Position
- 25900000
- Gross Proceeds
- 95000000
- Offering Price
- 1.72
- Shares Offered
- 55232558
- Shares Outstanding
- 43662403
- Greenshoe Shares
- 8284883
- Dilution Per Share
- 0.84
- Underwriting Discount
- 0.1032
Price after filing
Close on the filing date to close N calendar days later (from $1.39). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.